{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:53:02Z","timestamp":1771005182546,"version":"3.50.1"},"reference-count":45,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2\u03b1 (PGF2\u03b1) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to \u03b2-blockers. A novel convergent synthesis of 5 was developed employing Julia\u2013Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde \u03c9-chain synthon 17. The use of the same prostaglandin phenylsulfone 16, as a starting material in parallel syntheses of all commercially available antiglaucoma PGF2\u03b1 analogs 2\u20135, significantly reduces manufacturing costs resulting from its synthesis on an industrial scale and development of technological documentation. Another key aspect of the route developed is deoxydifluorination of a trans-13,14-en-15-one 30 with Deoxo-Fluor. Subsequent hydrolysis of protecting groups and final esterification of acid 6 yielded tafluprost (5). The main advantages are the preparation of high purity tafluprost (5) and the application of comparatively cheap reagents. The preparation and identification of two other tafluprost acid derivatives, tafluprost methyl ester (32) and tafluprost ethyl amide (33), are also described.<\/jats:p>","DOI":"10.3390\/molecules22020217","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T10:30:44Z","timestamp":1485858644000},"page":"217","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost"],"prefix":"10.3390","volume":"22","author":[{"given":"Ma\u0142gorzata","family":"Krupa","sequence":"first","affiliation":[{"name":"Chemistry Department, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Chody\u0144ski","sequence":"additional","affiliation":[{"name":"Chemistry Department, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ostaszewska","sequence":"additional","affiliation":[{"name":"Chemistry Department, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8413-9290","authenticated-orcid":false,"given":"Piotr","family":"Cmoch","sequence":"additional","affiliation":[{"name":"Chemistry Department, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland"},{"name":"Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 42\/52, 01-224 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Dams","sequence":"additional","affiliation":[{"name":"Chemistry Department, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00044-016-1563-5","article-title":"Prostaglandin analogues: Current treatment opinion for glaucoma","volume":"25","author":"Piplani","year":"2016","journal-title":"Med. Chem. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.prostaglandins.2013.01.001","article-title":"Therapeutic uses of prostaglandin F2\u03b1 analogues in ocular disease and novel synthetic strategies","volume":"104\u2013105","author":"Dams","year":"2013","journal-title":"Prostaglandins. Other Lipid Med."},{"key":"ref_3","first-page":"543","article-title":"An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: Place in therapy","volume":"8","author":"Fung","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00002512-200320080-00005","article-title":"Latanoprost: An update of its use in glaucoma and ocular hypertension","volume":"20","author":"Perry","year":"2003","journal-title":"Drugs Aging"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00002512-200219060-00005","article-title":"Travoprost","volume":"19","author":"Waugh","year":"2002","journal-title":"Drugs Aging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00002512-200219030-00008","article-title":"Topical bimatoprost: A review of its use in open-angle glaucoma and ocular hypertension","volume":"19","author":"Easthope","year":"2002","journal-title":"Drugs Aging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1358\/dot.2010.46.6.1482107","article-title":"A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension","volume":"46","author":"Hommer","year":"2010","journal-title":"Drugs Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1358\/dof.2006.031.09.1030940","article-title":"Tafluprost","volume":"31","author":"Wang","year":"2006","journal-title":"Drugs Future"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.tetlet.2003.12.029","article-title":"Synthesis of the highly potent prostanoid FP receptor agonist, AFP-168: A novel 15-deoxy-15,15-difluoroprostaglandin F2\u03b1 derivative","volume":"45","author":"Matsumura","year":"2004","journal-title":"Tetrahedron Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2147\/OPTH.S6369","article-title":"Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension","volume":"4","author":"Pozarowska","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1345\/aph.1R229","article-title":"Tafluprost: The first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension","volume":"46","author":"Swymer","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/bjophthalmol-2012-303026","article-title":"Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension","volume":"97","author":"Konstas","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exer.2003.12.007","article-title":"Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug","volume":"78","author":"Takagi","year":"2004","journal-title":"Exp. Eye Res."},{"key":"ref_14","unstructured":"Merck Sharpe & Dohme Ltd. (2014). SAFLUTAN 15 Micrograms\/ml, Eye Drops, Solution, in Single-Dose Container: UK Summary of Product Characteristics, Available online: http:\/\/www.mhra.gov.uk\/spc-pil\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/ja01048a062","article-title":"Stereo-controlled synthesis of prostaglandins F2\u03b1 and E2 (dl)","volume":"91","author":"Corey","year":"1969","journal-title":"J. Am. Chem. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1021\/ja00705a609","article-title":"Total synthesis of prostaglandins F2\u03b1 and E2 as the naturally occurring forms","volume":"92","author":"Corey","year":"1970","journal-title":"J. Am. Chem. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1021\/ja00711a083","article-title":"Total synthesis of prostaglandins F1\u03b1, E1, and E2 (natural forms) from a common synthetic intermediate","volume":"92","author":"Corey","year":"1970","journal-title":"J. Am. Chem. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/anie.199104553","article-title":"The logic of chemical synthesis: Multistep synthesis of complex carbogenic molecules (Nobel lecture)","volume":"30","author":"Corey","year":"1991","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/jm00054a008","article-title":"Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agents","volume":"36","author":"Resul","year":"1993","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jlcr.441","article-title":"Synthesis of [phenyl-2-3H]-travoprost: Isopropyl ester prodrug of a selective prostaglandin FP receptor agonist","volume":"44","author":"Selliah","year":"2001","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1021\/cr00020a007","article-title":"Synthesis of therapeutically useful prostaglandin and prostacyclin analogs","volume":"93","author":"Collins","year":"1993","journal-title":"Chem. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/jm00002a011","article-title":"Derivatives of 17-phenyl-18,19,20-trinorprostaglandin F2\u03b1 isopropyl ester: Potential antiglaucoma agents","volume":"38","author":"Liljebris","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_23","unstructured":"Bowler, J., and Crossley, N.S. (1974). Cyclopentane Derivatives. (1,350,971), GB Patent."},{"key":"ref_24","unstructured":"Gutman, A., Nisnevich, G., Etinger, M., Zaltzman, I., Yudovich, L., Pertsikov, B., and Tishin, B. (2005). Process for the Preparation of Prostaglandin Derivatives. (2005\/0209337 A1), U.S. Patent."},{"key":"ref_25","unstructured":"Woodward, D.F., Andres, S.W., Burk, R.M., and Garst, M.E. (1994). Non-Acidic Cyclopentane Heptanoic Acid, 2-Cycloalkyl or Arylalkyl Derivatives as Therapeutic Agents. (WO 94\/06433)."},{"key":"ref_26","unstructured":"Henegar, K.E. (2003). Process and Intermediates to Prepare Latanoprost. (2003\/0187071 A1), US Patent."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ejoc.200600749","article-title":"A new synthetic approach to high-purity (15R)-latanoprost","volume":"4","author":"Martynow","year":"2007","journal-title":"Eur. J. Org. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.tet.2012.11.087","article-title":"A novel convergent synthesis of the potent antiglaucoma agent travoprost","volume":"69","author":"Dams","year":"2013","journal-title":"Tetrahedron"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/chir.22123","article-title":"A novel convergent synthesis of the antiglaucoma PGF2\u03b1 analogue bimatoprost","volume":"25","author":"Dams","year":"2013","journal-title":"Chirality"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br. J. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/cosmetics3010004","article-title":"High performance liquid chromatography tandem mass spectrometry measurement of bimatoprost, latnaoprost and travoprost in eyelash enhancing cosmetic serums","volume":"3","author":"Marchei","year":"2016","journal-title":"Cosmetics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1248\/bpb.26.1691","article-title":"New fluoroprostaglandin F2\u03b1 derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents","volume":"26","author":"Nakajima","year":"2003","journal-title":"Biol. Pharm. Bull."},{"key":"ref_33","unstructured":"Shirasawa, E., Kageyama, M., Nakajima, T., Nakano, T., Mori, N., Sasakura, H., Matsumura, Y., and Morizawa, Y. (1998). Difluoroprostaglandin Derivatives and Their Use. (0850926 A2), EP Patent."},{"key":"ref_34","unstructured":"Brinkenhoff, M.C. (2011). Composition, Metod and Kit for Enhancing Hair. (2011\/0293549 A1), US Patent."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1016\/S0040-4039(01)87348-2","article-title":"Syntheses a l\u2019aide de sulfones V(+)\u2014methode de synthese generale de doubles liaisone","volume":"14","author":"Julia","year":"1973","journal-title":"Tetrahedron Lett."},{"key":"ref_36","first-page":"829","article-title":"Scope and stereochemistry of an olefin synthesis from \u03b2-hydroxysulphones","volume":"1","author":"Lythgoe","year":"1978","journal-title":"J. Chem. Soc. Perkin Trans."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/03086648508073398","article-title":"Recent sulphone-based olefination reactions","volume":"24","year":"1985","journal-title":"Phosphorus Sulphur Relat. Elem."},{"key":"ref_38","unstructured":"For synthesis of (S)-26 and (R)-18 enantiomers see: \n\t\t\t\t\t\t          \n\t\t\t\t\t\t            \n\t\t\t\t\t\t              Lin\n\t\t\t\t\t\t              P.\n\t\t\t\t\t\t            \n\t\t\t\t\t\t            \n\t\t\t\t\t\t              Chang\n\t\t\t\t\t\t              L.\n\t\t\t\t\t\t            \n\t\t\t\t\t\t            \n\t\t\t\t\t\t              Edmondson\n\t\t\t\t\t\t              S.D.\n\t\t\t\t\t\t            \n\t\t\t\t\t\t          \n\t\t\t\t\t\t          Pyrrolidine-Derived beta 3 Adrenergic Receptor Agonists\n\t\t\t\t\t\t          WO Patent\n\t\t\t\t\t\t          2010\/129326 A1\n\t\t\t\t\t\t          11\n\t\t\t\t\t\t          November\n\t\t\t\t\t\t          2010"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1016\/S0040-4039(00)71334-7","article-title":"Desulfonylation of aryl alkyl sulfones","volume":"17","author":"Trost","year":"1976","journal-title":"Tetrahedron Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1039\/B500713E","article-title":"Ethyl (benzothiol-2-ylsulfonyl)acetate: A new reagent for the stereoselective synthesis of \u03b1,\u03b2-unsaturated esters from aldehydes","volume":"3","author":"Blakemore","year":"2005","journal-title":"Org. Biomol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1021\/jo00170a070","article-title":"Readily accessible 12-I-51 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones","volume":"48","author":"Dess","year":"1983","journal-title":"J. Org. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1021\/ol902039q","article-title":"Aminodifluorosulfinium tetrafluoroborate salts as stable and crystalline deoxofluorinating reagents","volume":"11","author":"Beaulieu","year":"2009","journal-title":"Org. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1021\/jo100504x","article-title":"Aminodifluorosulfinium salts: Selective fluorination reagents with enhanced thermal stability and ease of handling","volume":"75","author":"Beaulieu","year":"2010","journal-title":"J. Org. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0022-1139(94)03126-K","article-title":"Introduction st\u00e9r\u00e9os\u00e9lective du groupment difluorom\u00e9thyl\u00e8ne en position allylique","volume":"70","author":"Tellier","year":"1995","journal-title":"J. Fluorine Chem."},{"key":"ref_45","unstructured":"Wu, P., Wu, H., and Wen, W. (2016). Metal-Catalyzed Asymmetric 1,4-Conjugate Addition of Vinylboron Compounds to 2-Substituted-4-Oxy-Cyclopent-2-en-1-Ones Yielding Prostaglandins and Prostaglandin Analogs. (2016\/005943 A1), WO Patent."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/22\/2\/217\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:27:19Z","timestamp":1760207239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/22\/2\/217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,31]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2]]}},"alternative-id":["molecules22020217"],"URL":"https:\/\/doi.org\/10.3390\/molecules22020217","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,31]]}}}